A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The metric has seen a significant loss of -93.94% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -88.33%. Over the past 30 days, the price of ACRS has leaped by -82.06%. And in the last five days, it has fallen by -79.93%.
The stock of Aclaris Therapeutics Inc (ACRS) is currently priced at $0.95. In the last session, the stock climbed significantly, topping out at $1.04 after opening at $0.8987. The day’s lowest price was $0.8673 before the stock closed at $0.89.
The market performance of Aclaris Therapeutics Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $18.88 on 11/18/22, while the lowest value for the same duration was $0.59 on 11/13/23.
52-week price history of ACRS Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Aclaris Therapeutics Inc’s current trading price is -94.95% away from its 52-week high, while its distance from the 52-week low is 61.69%. The stock’s price range during this time has been between $0.59 and $18.88. The trading volume for the Healthcare sector company’s shares reached about 12.28 million for the day, which was higher than the average daily volume of 3.19 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Aclaris Therapeutics Inc (ACRS) has experienced a quarterly decline of -87.00% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 67.60M and boasts a workforce of 105 employees.
Aclaris Therapeutics Inc: Analysts’ Ratings Unveiled
As of right now, 9 analysts are rating Aclaris Therapeutics Inc as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 7.2393, with a change in price of -9.2957. Similarly, Aclaris Therapeutics Inc recorded 2,360,619 in trading volume during the last 100 days, posting a change of -90.69%.
ACRS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ACRS stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
ACRS Stock Stochastic Average
Today, Aclaris Therapeutics Inc’s raw stochastic average for the past 50 days stands at 4.74%, indicating a decline from the raw stochastic average of the last 20 days, which was 7.12%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 5.67% and 3.96% respectively.